Literature DB >> 8513455

Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.

L T Balemans1, V Mattijssen, P A Steerenberg, B E Van Driel, P H De Mulder, W Den Otter.   

Abstract

Therapy with repeated intratumoral and perilymphatic administration of relatively low doses of polyethylene-glycol(PEG)-modified interleukin-2 (IL-2) in the syngeneic guinea pig line 10 (L10) hepatocarcinoma results in significant local tumor growth inhibition and a delay in development of regional lymph node metastases of more than 3 weeks when compared to controls. Occasionally animals are cured of tumor. The mechanism of this antitumor activity was studied. The antitumor activity of locoregionally administered PEG-IL-2 was abrogated by pretreatment with polyclonal anti-thymocyte serum, indicating that the observed tumor growth inhibition was a T-cell-mediated phenomenon. Besides the locoregional tumor growth inhibition, a systemic effect was recorded as the growth of a second tumor cell inoculum at the contralateral side was inhibited as well. Furthermore, those animals cured after PEG-IL-2 therapy developed specific immunity against the L10 tumor and this immunity could be transferred to naive animals by spleen cells. Immunohistological observations of the tumor site revealed a slight increase of helper and cytotoxic T cell subpopulations after PEG-IL-2 therapy. More pronounced, however, was the rise in number of eosinophilic granulocytes present in the stroma surrounding the tumor cells. Involvement of cytotoxic cells in the antitumor effects of PEG-IL-2 could not be demonstrated: regional lymph node cells and spleen cells obtained immediately after therapy (day 15) or on day 21 showed no cytotoxic activity in vitro against L10, K562, Daudi and line 1 (L1) target cells. In conclusion, locoregional therapy with PEG-IL-2 induced a a systemic T-cell-mediated antitumor response. As no cytotoxic T cell activity was measured, however, the underlying mechanism is most likely a T-helper response. Eosinophils at the tumor site may be tumoricidal but further experiments must reveal the role of these cells in the PEG-IL-2-induced tumor regression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513455     DOI: 10.1007/BF01516936

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  43 in total

Review 1.  Mechanism of BCG induced regression of line 10 hepatocarcinoma in the guinea pig.

Authors:  P A Steerenberg; W H De Jong; E J Ruitenberg
Journal:  In Vivo       Date:  1991 Nov-Dec       Impact factor: 2.155

2.  Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells.

Authors:  D S Silberstein; D D Schoof; M L Rodrick; P C Tai; C J Spry; J R David; T J Eberlein
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

3.  Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: pathology and formation of ascites variant.

Authors:  H J Rapp; W H Churchill; B S Kronman; R T Rolley; W G Hammond; T Borsos
Journal:  J Natl Cancer Inst       Date:  1968-07       Impact factor: 13.506

4.  Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

Authors:  M J Knauf; D P Bell; P Hirtzer; Z P Luo; J D Young; N V Katre
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

5.  Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study.

Authors:  V P Rutten; W R Klein; W A De Jong; W Misdorp; W Den Otter; P A Steerenberg; W H De Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; M Giovarelli; M G Barioglio; G P Cavallo; C Jemma; G Forni
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

7.  Histophotometric estimation of volume density of collagen as an indication of fibrosis in rat liver.

Authors:  J James; K S Bosch; F M Zuyderhoudt; J M Houtkooper; J van Gool
Journal:  Histochemistry       Date:  1986

8.  Tumor infiltrating leukocytes (tils) during progressive tumor growth and BCG-mediated tumor regression.

Authors:  P A Steerenberg; W H De Jong; A Elgersma; R Burger; L G Poels; A M Claessen; W Den Otter; E J Ruitenberg
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1990

9.  Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies.

Authors:  N Flomenberg; K Welte; R Mertelsmann; R O'Reilly; B Dupont
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

10.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

Authors:  P J Spiess; J C Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

View more
  6 in total

1.  Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.

Authors:  H M Karpoff; M D'Angelica; S Blair; M D Brownlee; H Federoff; Y Fong
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors.

Authors:  T Nomura; N Koreeda; F Yamashita; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

3.  Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system.

Authors:  A Saikawa; T Nomura; F Yamashita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

4.  Locoregional IL-2 low dose applications for gastrointestinal tumors.

Authors:  Zachary Krastev; V Koltchakov; R Tomova; S Deredjian; A Alexiev; D Popov; B Tomov; Jan-Willem Koten; John Jacobs; Willem Den Otter
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

5.  Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells.

Authors:  L T Balemans; P A Steerenberg; B H Kremer; F J Koppenhagen; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

Review 6.  Interleukin 2-Based Fusion Proteins for the Treatment of Cancer.

Authors:  Alana MacDonald; T-C Wu; Chien-Fu Hung
Journal:  J Immunol Res       Date:  2021-11-08       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.